PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|November 11, 2013
DCAT Names Officers
Author(s)Pharmaceutical Technology Editors
Lyra Myers, associate director and value creation agent at Roche, has been elected DCAT president.
Advertisement
Lyra Myers, associate director and value creation agent at Roche, has been elected president of the Drug, Chemical & Associated Technologies Association (DCAT). Also elected to serve as officers of DCAT are: George Svokos, senior vice-president, product and portfolio management at Teva Pharmaceuticals U.S.A., as senior vice-president; Folker Ruchatz, senior vice-president, contract manufacturing business, biopharmaceuticals at Boehringer Ingelheim as finance officer; and Milton Boyer, president at OSO BioPharmaceuticals Manufacturing, LLC as vice-president. All will serve one-year terms.
DCAT is a nonprofit business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical, and related industries. The association provides services, programs and activities designed to support the business development objectives of its membership.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement